I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Jason McCarthy initiated a Buy rating on OS Therapies (OSTX) on August 18, citing the advancing OST-HER2 clinical program, upcoming regulatory catalysts including FDA and MHRA meetings, and an extended cash runway into 2027 supported by recent financing. Roth MKM also reiterated a Buy with a $7 price target. The stock has risen 33.9% over six months.
Maxim Group analyst Jason McCarthy has maintained their bullish stance on OSTX stock, giving a Buy rating on August 18.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors, including the advancing clinical program for OST-HER2 in metastatic osteosarcoma and the upcoming 3-year overall survival data, which follow statistically significant 2.5-year results. He also views the planned FDA and MHRA meetings, together with anticipated BLA and conditional marketing submissions, as key catalysts that could accelerate the path to commercialization.
Moreover, McCarthy notes that recent debt financing, expected VAT refunds, and UK R&D tax credits collectively enhance OS Therapies’ cash runway into 2027, supporting both the global Phase 3 study launch and potential commercialization efforts. While he anticipates higher operating expenses, he believes the strengthening balance sheet and value-creating regulatory milestones justify a favorable risk-reward profile, supporting his Buy recommendation on OSTX.
In another report released on August 18, Roth MKM also reiterated a Buy rating on the stock with a $7.00 price target.
OSTX’s price has also changed moderately for the past six months – from $1.180 to $1.580, which is a 33.90% increase.